2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

4:30PM-6:00PM: Abstract Number: 2886

Safety and Efficacy of Long-Time Intensified Rituximab Treatment in Patients with Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics II

4:30PM-6:00PM: Abstract Number: 2863

Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal

Rheumatoid Arthritis – Clinical Aspects V: Predicting Treatment Response

4:30PM-6:00PM: Abstract Number: 2857

Short and Long-Term Follow-up of Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

4:30PM-6:00PM: Abstract Number: 2869

Significant Decrease of T-Cells but Not Macrophages in the Synovium of Patients with Active Rheumatoid Arthritis after Treatment with Tocilizumab

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Pharmacodynamic Markers and Therapeutic Intervention

4:30PM-6:00PM: Abstract Number: 2824

Sleep and Depression Mediate the Relationship between Pain and Cognitive Dysfunction in Lupus Patients

ARHP: Exemplary Abstracts

4:30PM-6:00PM: Abstract Number: 2855

Subcutaneous Abatacept in Patients Aged 2–17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

4:30PM-6:00PM: Abstract Number: 2879

Switching from Adalimumab to Chs-1420: A Randomized, Double-Blind Global Clinical Trial in Patients with Psoriasis and Psoriatic Arthritis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV

4:30PM-6:00PM: Abstract Number: 2885

Tadalafil Reduces Skin Fibrosis and Profibrotic Genes Expression in Patients with Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics II

4:30PM-6:00PM: Abstract Number: 2836

The Additional Economic Burden of Depression Among Adults with Rheumatoid Arthritis in the United States

Health Services Research I: Cost Drivers in Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 2843

The Relationship between Serum Urate Concentration and Incident Gout: An Individual Participant Data Analysis

Metabolic and Crystal Arthropathies I: Gout Risk of Disease Activity, Cardiovascular Disease and Mortality

4:30PM-6:00PM: Abstract Number: 2847

The Sons of Gout Study. Ultrasonographic Evaluation of Asymptomatic Monosodium Urate Crystal Deposition in Sons of People with Gout

Metabolic and Crystal Arthropathies I: Gout Risk of Disease Activity, Cardiovascular Disease and Mortality

4:30PM-6:00PM: Abstract Number: 2865

The Utility and Limitations of Serum C-Reactive Protein in Appraising Synovial Inflammation

Rheumatoid Arthritis – Clinical Aspects V: Predicting Treatment Response

4:30PM-6:00PM: Abstract Number: 2874

Thymic Stromal Lymphopoietin (TSLP) Expression Is Associated with Lymphoproliferation and Lymphoma in Primary Sjögren’s Syndrome

Sjögren's Syndrome II: Pathogenesis, Autoantibodies and T-Cells

4:30PM-6:00PM: Abstract Number: 2861

Treat-to-Target in Rheumatoid Arthritis: What Level of Treatment Response Is Necessary By 3 Months in Order to Achieve the Treatment Target By 6 Months? Results from the Real Life NOR-DMARD Study

Rheumatoid Arthritis – Clinical Aspects V: Predicting Treatment Response

4:30PM-6:00PM: Abstract Number: 2842

Usefulness of Polymerase Chain Reaction for Diagnosing Whipple’S Disease in Rheumatology

Infection-related Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].